Several promising directions are in clinical trials, but nothing is close to broad approval, and the honest answer is that there is no cure yet for chronic tinnitus.
The most advanced candidates are bimodal stimulation devices that pair sound with tongue or skin stimulation — Lenire, Neuromod's device, received CE marking in 2019 and FDA marketing authorisation in 2023, with reasonable trial results showing modest reductions in tinnitus severity for many but not all users. It is not a cure; it is the first device-based treatment with regulatory backing. Cost remains high.
Hair-cell regeneration research is genuinely exciting in the long term, but human therapies remain years away. Drugs targeting glutamate signalling at the inner-ear synapse have failed multiple late-stage trials so far. Vagus-nerve stimulation paired with tones has interesting early data.
The biggest near-term gains for most people still come from a workmanlike combination of hearing aids (where indicated), structured CBT, sound enrichment, and time. That is unglamorous, and it works.
Be sceptical of anyone selling a cure today. Real treatments will go through proper trials and regulators.